NasdaqGS - Nasdaq Real Time Price USD

Spero Therapeutics, Inc. (SPRO)

1.4300 +0.0100 (+0.70%)
As of 12:02 PM EDT. Market Open.

Key Executives

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Dr. Ankit Mahadevia M.D., MBA Co-Founder & Chairman of the Board 1.39M -- 1981
Mr. Satyavrat Shukla C.F.A. President, CEO & Director 1.12M -- 1973
Mr. Timothy Keutzer Chief Operating Officer 938.57k -- 1968
Ms. Esther P. Rajavelu CFO, Chief Business Officer & Treasurer -- -- 1979
Mr. James P. Brady Chief Human Resource Officer -- -- --
Dr. Kamal Hamed M.B.A., M.D., M.P.H. Chief Medical Officer -- -- 1961

Spero Therapeutics, Inc.

675 Massachusetts Avenue
14th Floor
Cambridge, MA 02139
United States
857 242 1600 https://sperotherapeutics.com
Sector: 
Healthcare
Industry: 
Biotechnology
Full Time Employees: 
46

Description

Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa, as well as negative bacterial infections in the hospital setting; and SPR720, a novel oral antibiotic agent for the treatment of non-tuberculous mycobacterial pulmonary disease. It has license agreement with Meiji Seika Pharma Co., Ltd. to support the development of tebipenem HBr; Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries; and Vertex Pharmaceuticals Incorporated for patents relating to SPR720, as well as SPR719, an active metabolite. Spero Therapeutics, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.

Corporate Governance

Spero Therapeutics, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Recent Events

  • Apr 16, 2024
    DEF 14A: Proxy Statements
    See Full Filing
  • Mar 29, 2024
    8-K: Corporate Changes & Voting Matters
    See Full Filing
  • Mar 20, 2024
    CORRESP: A correspondence can be sent as a document with another submission type or can be sent as a separate submission
    See Full Filing
  • Mar 15, 2024
    S-8: Offering Registrations
    See Full Filing
  • Mar 13, 2024
    10-K: Periodic Financial Reports
    See Full Filing

Upcoming Events

May 09, 2024 - May 13, 2024
Spero Therapeutics, Inc. Earnings Call

Related Tickers

ASMB Assembly Biosciences, Inc.
13.17
-2.08%
 
CTMX CytomX Therapeutics, Inc.
1.6150
-0.92%
 
EIGRQ Eiger BioPharmaceuticals, Inc.
3.1300
-17.58%
 
TIL Instil Bio, Inc.
10.21
-3.68%
 
GLPG.AS Galapagos NV
26.56
-2.06%
 
CLRB Cellectar Biosciences, Inc.
3.0300
-0.98%
 
NXTC NextCure, Inc.
1.3750
-4.56%
 
ALGS Aligos Therapeutics, Inc.
0.8000
-3.50%
 
SYBX Synlogic, Inc.
1.8750
-0.27%
 
PRTC.L PureTech Health plc
212.50
0.00%